Nuclear bile acid signaling through the farnesoid X receptor

Cellular and Molecular Life Sciences

Volumn 72, Issue 9, 2015, Pages 1631-1650

  Mazuy, Claire ^a,b,c,d   Helleboid, Audrey ^a,b,c,d   Staels, Bart ^a,b,c,d   Lefebvre, Philippe ^a,b,c,d  

^a France   (France)

^b INSERM UMR1011 Bâtiment JandK ^*  (France)

^c UNIV LILLE   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Bile acids; FXR; Homeostasis; Metabolism; Nuclear receptor

Indexed keywords

BILE ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; GLUCOSE; LIPOPROTEIN;

ANIMAL; CHEMISTRY; GENETICS; HOMEOSTASIS; HUMAN; LIPID METABOLISM; METABOLISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; BILE ACIDS AND SALTS; GLUCOSE; HOMEOSTASIS; HUMANS; LIPID METABOLISM; LIPOPROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84931317994     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-014-1805-y     Document Type: Review

References (229)

1. Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137-174
2. Russell DW, Setchell KD (1992) Bile acid biosynthesis. Biochemistry 31:4737-4749
3. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall H, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17:225-235
4. Kwakye JB, Barnes S, Diasio RB (1993) Identification of bile acid coenzyme a synthetase in rat kidney. J Lipid Res 34:95-99
5. Falany CN, Johnson MR, Barnes S, Diasio RB (1994) Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J Biol Chem 269:19375-19379
6. Solaas K, Ulvestad A, Söreide O, Kase BF (2000) Subcellular organization of bile acid amidation in human liver: a key issue in regulating the biosynthesis of bile salts. J Lipid Res 41:1154-1162
7. Jansen PL, Mulder GJ, Burchell B, Bock KW (1992) New developments in glucuronidation research: report of a workshop on "glucuronidation, its role in health and disease". Hepatology 15:532-544
8. Stiehl A (1977) Disturbances of bile acid metabolism in cholestasis. Clin Gastroenterol 6:45-67
9. Yousef I, Mignault D, Tuchweber B (1992) Effect of complete sulfation of bile acids on bile formation: role of conjugation and number of sulfate groups. Hepatology 15:438-445
10. Elferink RPJO, Ottenhoff R, Fricker G, Seward DJ, Ballatori N, Boyer J (2004) Lack of biliary lipid excretion in the little skate, Raja erinacea, indicates the absence of functional Mdr2, Abcg5, and Abcg8 transporters. Am J Physiol Gastrointest Liver Physiol 286:G762-G768
11. García-Cañaveras JC, Donato MT, Castell JV, Lahoz A (2012) Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J Lipid Res 53:2231-2241
12. Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L (1986) Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 19:57-69
13. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E (2011) Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci USA 108(Suppl 1):4523-4530
14. Ridlon JM, Kang D, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241-259
15. Meier PJ, Stieger B (2002) Bile salt transporters. Annu Rev Physiol 64:635-661
16. Riottot M, Sacquet E (1985) Increase in the ileal absorption rate of sodium taurocholate in germ-free or conventional rats given an amylomaize-starch diet. Br J Nutr 53:307-310
17. Gustafsson BE, Bergstrom S, Lindstedt S, Norman A (1957) Turnover and nature of fecal bile acids in germfree and infected rats fed cholic acid-24-14C; bile acids and steroids 41. Proc Soc Exp Biol Med 94:467-471
18. Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ (2013) Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 4:2384
19. Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A (2014) Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 7:12-18
20. Tilg H, Moschen AR (2014) Microbiota and diabetes: an evolving relationship. Gut 63:1513-1521
21. Vincent RP, Omar S, Ghozlan S, Taylor DR, Cross G, Sherwood RA, Fandriks L, Olbers T, Werling M, Alaghband-Zadeh J, le Roux CW (2013) Higher circulating bile acid concentrations in obese patients with type 2 diabetes. Ann Clin Biochem 50:360-364
22. Wewalka M, Patti M, Barbato C, Houten SM, Goldfine AB (2014) Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. J Clin Endocrinol Metab 99:1442-1451
23. Steiner C, Othman A, Saely CH, Rein P, Drexel H, von Eckardstein A, Rentsch KM (2011) Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS ONE 6:e25006
24. Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F, Hill C, Gahan CGM (2014) Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci USA 111:7421-7426
25. Begley M, Gahan CGM, Hill C (2005) The interaction between bacteria and bile. FEMS Microbiol Rev 29:625-651
26. Trauner M, Fickert P, Tilg H (2013) Bile acids as modulators of gut microbiota linking dietary habits and inflammatory bowel disease: a potentially dangerous liaison. Gastroenterology 144:844-846
27. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS (2014) Bile acids and the gut microbiome. Curr Opin Gastroenterol 30:332-338
28. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ et al (1994) The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19:1149-1156
29. Poupon RE, Poupon R, Balkau B (1994) Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 330:1342-1347
30. Combes B, Carithers RLJ, Maddrey WC, Lin D, McDonald MF, Wheeler DE, Eigenbrodt EH, Muñoz SJ, Rubin R, Garcia-Tsao G et al (1995) A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22:759-766
31. Lindor KD, Dickson ER, Jorgensen RA, Anderson ML, Wiesner RH, Gores GJ, Lange SM, Rossi SS, Hofmann AF, Baldus WP (1995) The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 22:1158-1162
32. Kuiper EMM, Hansen BE, Lesterhuis W, Robijn RJ, Thijs JC, Engels LGJB, Koek GH, Aparicio MN, Kerbert-Dreteler MJ, van Buuren HR (2011) The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. Clin Res Hepatol Gastroenterol 35:29-33
33. Glantz A, Reilly S, Benthin L, Lammert F, Mattsson L, Marschall H (2008) Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology 47:544-551
34. Jazrawi RP, de Caestecker JS, Goggin PM, Britten AJ, Joseph AE, Maxwell JD, Northfield TC (1994) Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 106:134-142
35. Combes B, Markin RS, Wheeler DE, Rubin R, West AB, Mills AS, Eigenbrodt EH, Maddrey WC, Munoz SJ, Garcia-Tsao G, Bonner GF, Boyer JL, Luketic VA, Shiffman ML, Peters MG, White HM, Zetterman RK, Carithers RLJ (1999) The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 30:602-605
36. Hofmann AF, Hagey LR (2014) Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res 55:1553-1595
37. Out C, Groen AK, Brufau G (2012) Bile acid sequestrants: more than simple resins. Curr Opin Lipidol 23:43-55
38. Goldberg RB, Rosenson RS, Hernandez-Triana E, Misir S, Jones MR (2013) Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia. Diab Vasc Dis Res 10:256-262
39. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR (2008) Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31:1479-1484
40. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL (2007) Results of the glucose-lowering effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 29:74-83
41. Goldberg RB, Fonseca VA, Truitt KE, Jones MR (2008) Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 168:1531-1540
42. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284:1365-1368
43. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B (1999) Identification of a nuclear receptor for bile acids. Science 284:1362-1365
44. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 98:3369-3374
45. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ (2002) Vitamin D receptor as an intestinal bile acid sensor. Science 296:1313-1316
46. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M (2003) A G protein-coupled receptor responsive to bile acids. J Biol Chem 278:9435-9440
47. Stepanov V, Stankov K, Mikov M (2013) The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J Recept Signal Transduct Res 33:213-223
48. Keitel V, Häussinger D (2012) Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol 36:412-419
49. Zwart W, de Leeuw R, Rondaij M, Neefjes J, Mancini MA, Michalides R (2010) The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. J Cell Sci 123:1253-1261
50. Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, Gunyuzlu PL, Haws TF, Kassam A, Powell F, Hollis GF, Young PR, Mukherjee R, Burn TC (2002) Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290:35-43
51. Zhang Y, Kast-Woelbern HR, Edwards PA (2003) Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 278:104-110
52. Vaquero J, Monte MJ, Dominguez M, Muntané J, Marin JJG (2013) Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. Biochem Pharmacol 86:926-939
53. Popescu IR, Helleboid-Chapman A, Lucas A, Vandewalle B, Dumont J, Bouchaert E, Derudas B, Kerr-Conte J, Caron S, Pattou F, Staels B (2010) The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett 584:2845-2851
54. Anaya-Hernández A, Méndez-Tepepa M, Laura GH, Pacheco P, Martínez-Gómez M, Castelán F, Cuevas E (2014) Farnesoid X receptor immunolocalization in reproductive tissues of adult female rabbits. Acta Histochem 116:1068-1074
55. Bishop-Bailey D, Walsh DT, Warner TD (2004) Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 101:3668-3673
56. Lee FY, Kast-Woelbern HR, Chang J, Luo G, Jones SA, Fishbein MC, Edwards PA (2005) Alpha-crystallin is a target gene of the farnesoid X-activated receptor in human livers. J Biol Chem 280:31792-31800
57. Anisfeld AM, Kast-Woelbern HR, Meyer ME, Jones SA, Zhang Y, Williams KJ, Willson T, Edwards PA (2003) Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. J Biol Chem 278:20420-20428
58. Anisfeld AM, Kast-Woelbern HR, Lee H, Zhang Y, Lee FY, Edwards PA (2005) Activation of the nuclear receptor FXR induces fibrinogen expression: a new role for bile acid signaling. J Lipid Res 46:458-468
59. Song X, Chen Y, Valanejad L, Kaimal R, Yan B, Stoner M, Deng R (2013) Mechanistic insights into isoform-dependent and species-specific regulation of bile salt export pump by farnesoid X receptor. J Lipid Res 54:3030-3044
60. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:731-744
61. Prawitt J, Abdelkarim M, Stroeve JHM, Popescu I, Duez H, Velagapudi VR, Dumont J, Bouchaert E, van Dijk TH, Lucas A, Dorchies E, Daoudi M, Lestavel S, Gonzalez FJ, Oresic M, Cariou B, Kuipers F, Caron S, Staels B (2011) Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60:1861-1871
62. Lambert G, Amar MJA, Guo G, Brewer HBJ, Gonzalez FJ, Sinal CJ (2003) The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 278:2563-2570
63. Hanniman EA, Lambert G, McCarthy TC, Sinal CJ (2005) Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein e-deficient mice. J Lipid Res 46:2595-2604
64. -/- mice. Arterioscler Thromb Vasc Biol 26:2316-2321
65. Kong B, Luyendyk JP, Tawfik O, Guo GL (2009) Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 328:116-122
66. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart J, Gonzalez FJ, Kuipers F, Staels B (2006) The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281:11039-11049
67. Ma K, Saha PK, Chan L, Moore DD (2006) Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116:1102-1109
68. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 103:1006-1011
69. Zhang Y, Ge X, Heemstra LA, Chen W, Xu J, Smith JL, Ma H, Kasim N, Edwards PA, Novak CM (2012) Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in Ob/Ob mice. Mol Endocrinol 26:272-280
70. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W (2007) Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 67:863-867
71. Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL, Apte U (2011) Increased activation of the Wnt/Β-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther 338:12-21
72. -/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expression. Mol Endocrinol 26:775-785
73. Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, Dong B, Huang X, Moore DD (2006) Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312:233-236
74. Meng Z, Wang Y, Wang L, Jin W, Liu N, Pan H, Liu L, Wagman L, Forman BM, Huang W (2010) FXR regulates liver repair after CCl4-induced toxic injury. Mol Endocrinol 24:886-897
75. Maran RRM, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D, Gao X, Zhang Y, Ganapathy V, Gonzalez FJ, Guo GL (2009) Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther 328:469-477
76. Kok T, Hulzebos CV, Wolters H, Havinga R, Agellon LB, Stellaard F, Shan B, Schwarz M, Kuipers F (2003) Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem 278:41930-41937
77. -/- mice. J Biol Chem 284:10315-10323
78. Bjursell M, Wedin M, Admyre T, Hermansson M, Böttcher G, Göransson M, Lindén D, Bamberg K, Oscarsson J, Bohlooly-Y M (2013) Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS ONE 8:e64721
79. Li G, Thomas AM, Hart SN, Zhong X, Wu D, Guo GL (2010) Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small heterodimer partner. Mol Endocrinol 24:1404-1412
80. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6:507-515
81. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6:517-526
82. Sanyal S, Båvner A, Haroniti A, Nilsson L, Lundåsen T, Rehnmark S, Witt MR, Einarsson C, Talianidis I, Gustafsson J, Treuter E (2007) Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc Natl Acad Sci USA 104:15665-15670
83. Abrahamsson A, Gustafsson U, Ellis E, Nilsson L, Sahlin S, Björkhem I, Einarsson C (2005) Feedback regulation of bile acid synthesis in human liver: importance of HNF-4alpha for regulation of CYP7A1. Biochem Biophys Res Commun 330:395-399
84. Ellis E, Axelson M, Abrahamsson A, Eggertsen G, Thörne A, Nowak G, Ericzon B, Björkhem I, Einarsson C (2003) Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor. Hepatology 38:930-938
85. Liu J, Lu H, Lu Y, Lei X, Cui JY, Ellis E, Strom SC, Klaassen CD (2014) Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci
86. Pandak WM, Bohdan P, Franklund C, Mallonee DH, Eggertsen G, Björkhem I, Gil G, Vlahcevic ZR, Hylemon PB (2001) Expression of sterol 12alpha-hydroxylase alters bile acid pool composition in primary rat hepatocytes and in vivo. Gastroenterology 120:1801-1809
87. Zollner G, Wagner M, Fickert P, Geier A, Fuchsbichler A, Silbert D, Gumhold J, Zatloukal K, Kaser A, Tilg H, Denk H, Trauner M (2005) Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Am J Physiol Gastrointest Liver Physiol 289:G798-G805
88. Maeda T, Miyata M, Yotsumoto T, Kobayashi D, Nozawa T, Toyama K, Gonzalez FJ, Yamazoe Y, Tamai I (2004) Regulation of drug transporters by the farnesoid X receptor in mice. Mol Pharm 1:281-289
89. Plass JRM, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PLM, Müller M (2002) Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 35:589-596
90. Lee FY, de Aguiar Vallim TQ, Chong HK, Zhang Y, Liu Y, Jones SA, Osborne TF, Edwards PA (2010) Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity. Mol Endocrinol 24:1626-1636
91. Song K, Li T, Owsley E, Strom S, Chiang JYL (2009) Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49:297-305
92. Zhan L, Liu H, Fang Y, Kong B, He Y, Zhong X, Fang J, Wan YY, Guo GL (2014) Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes. PLoS ONE 9:e105930
93. Zhou W, Feng X, Wu Y, Benge J, Zhang Z, Chen Z (2009) FGF-receptor substrate 2 functions as a molecular sensor integrating external regulatory signals into the FGF pathway. Cell Res 19:1165-1177
94. Kong B, Wang L, Chiang JYL, Zhang Y, Klaassen CD, Guo GL (2012) Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 56:1034-1043
95. Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, Moschetta A (2012) Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142:355-365
96. Stroeve JHM, Brufau G, Stellaard F, Gonzalez FJ, Staels B, Kuipers F (2010) Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. Lab Invest 90:1457-1467
97. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217-225
98. Li S, Hsu DDF, Li B, Luo X, Alderson N, Qiao L, Ma L, Zhu HH, He Z, Suino-Powell K, Ji K, Li J, Shao J, Xu HE, Li T, Feng G (2014) Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell Metab 20:320-332
99. Kir S, Zhang Y, Gerard RD, Kliewer SA, Mangelsdorf DJ (2012) Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem 287:41334-41341
100. Chen F, Ma L, Dawson PA, Sinal CJ, Sehayek E, Gonzalez FJ, Breslow J, Ananthanarayanan M, Shneider BL (2003) Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J Biol Chem 278:19909-19916
101. Hwang ST, Urizar NL, Moore DD, Henning SJ (2002) Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid X receptor. Gastroenterology 122:1483-1492
102. Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai S, Moustafa T, Zollner G, Lee JY, Ballatori N (2006) Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 290:G1124-G1130
103. Cui YJ, Aleksunes LM, Tanaka Y, Goedken MJ, Klaassen CD (2009) Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol Sci 110:47-60
104. Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, Sabatino G, Russo G, Castellani D, Willson TM, Pruzanski M, Pellicciari R, Morelli A (2005) Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 313:604-612
105. Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112:1678-1687
106. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pellicciari R, Morelli A (2004) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127:1497-1512
107. Stedman C, Liddle C, Coulter S, Sonoda J, Alvarez JG, Evans RM, Downes M (2006) Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci USA 103:11323-11328
108. Marschall H, Wagner M, Bodin K, Zollner G, Fickert P, Gumhold J, Silbert D, Fuchsbichler A, Sjövall J, Trauner M (2006) Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J Lipid Res 47:582-592
109. Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, Zatloukal K, Guo GL, Schuetz JD, Gonzalez FJ, Marschall H, Denk H, Trauner M (2003) Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 125:825-838
110. Kazgan N, Metukuri MR, Purushotham A, Lu J, Rao A, Lee S, Pratt-Hyatt M, Lickteig A, Csanaky IL, Zhao Y, Dawson PA, Li X (2014) Intestine-specific deletion of SIRT1 in mice impairs DCoH2-HNF-1α-FXR signaling and alters systemic bile acid homeostasis. Gastroenterology 146:1006-1016
111. Lefebvre P, Staels B (2014) DCo(H2)Ding the Metabolic Functions of SIRT1 in the Intestine. Gastroenterology 146:893-896
112. Alvarez L, Jara P, Sánchez-Sabaté E, Hierro L, Larrauri J, Díaz MC, Camarena C, De la Vega A, Frauca E, López-Collazo E, Lapunzina P (2004) Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum Mol Genet 13:2451-2460
113. Chen F, Ananthanarayanan M, Emre S, Neimark E, Bull LN, Knisely AS, Strautnieks SS, Thompson RJ, Magid MS, Gordon R, Balasubramanian N, Suchy FJ, Shneider BL (2004) Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 126:756-764
114. Zimmer V, Müllenbach R, Simon E, Bartz C, Matern S, Lammert F (2009) Combined functional variants of hepatobiliary transporters and FXR aggravate intrahepatic cholestasis of pregnancy. Liver Int 29:1286-1288
115. Langhi C, Le May C, Kourimate S, Caron S, Staels B, Krempf M, Costet P, Cariou B (2008) Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett 582:949-955
116. Wang Y, Jones PJH, Woollett LA, Buckley DD, Yao L, Granholm NA, Tolley EA, Heubi JE (2006) Effects of chenodeoxycholic acid and deoxycholic acid on cholesterol absorption and metabolism in humans. Transl Res 148:37-45
117. Pérez-Aguilar F, Bretó M, Alegre B, Berenguer J (1985) Increase in serum total cholesterol and low-density lipoprotein cholesterol by high-dose chenodeoxycholic acid in patients with radiolucent gallstones significantly reversed during preventive low dose after gallstone dissolution. Digestion 31:225-233
118. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall H, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D (2013) Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145:574-582
119. Gautier T, de Haan W, Grober J, Ye D, Bahr MJ, Claudel T, Nijstad N, Van Berkel TJC, Havekes LM, Manns MP, Willems SM, Hogendoorn PCW, Lagrost L, Kuipers F, Van Eck M, Rensen PCN, Tietge UJF (2013) Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. J Lipid Res 54:2195-2205
120. Urizar NL, Dowhan DH, Moore DD (2000) The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J Biol Chem 275:39313-39317
121. Sirvent A, Verhoeven AJM, Jansen H, Kosykh V, Darteil RJ, Hum DW, Fruchart J, Staels B (2004) Farnesoid X receptor represses hepatic lipase gene expression. J Lipid Res 45:2110-2115
122. Leiss O, von Bergmann K (1982) Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. Scand J Gastroenterol 17:587-592
123. Hambruch E, Miyazaki-Anzai S, Hahn U, Matysik S, Boettcher A, Perović-Ottstadt S, Schlüter T, Kinzel O, Krol HD, Deuschle U, Burnet M, Levi M, Schmitz G, Miyazaki M, Kremoser C (2012) Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J Pharmacol Exp Ther 343:556-567
124. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113:1408-1418
125. Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R (2004) Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem 279:45685-45692
126. Cipriani S, Mencarelli A, Palladino G, Fiorucci S (2010) FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in zucker (Fa/Fa) obese rats. J Lipid Res 51:771-784
127. Schmitt J, Kong B, Stieger B, Tschopp O, Schultze SM, Rau M, Weber A, Müllhaupt B, Guo GL,Geier A (2014) Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. Liver Int
128. Zhang S, Wang J, Liu Q, Harnish DC (2009) Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 51:380-388
129. Porez G, Gross B, Prawitt J, Gheeraert C, Berrabah W, Alexandre J, Staels B, Lefebvre P (2013) The hepatic orosomucoid/Α1-acid glycoprotein gene cluster is regulated by the nuclear bile acid receptor FXR. Endocrinology 154:3690-3701
130. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart J, Kuipers F, Staels B (2004) Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53:890-898
131. Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, Arita E, Mataki C, Sato H, Tanigawara Y, Schoonjans K, Itoh H, Auwerx J (2011) Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem 286:26913-26920
132. Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, Gonzalez FJ, Fruchart J, Kuipers F, Staels B (2005) The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 280:29971-29979
133. Caron S, Huaman Samanez C, Dehondt H, Ploton M, Briand O, Lien F, Dorchies E, Dumont J, Postic C, Cariou B, Lefebvre P, Staels B (2013) Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol Cell Biol 33:2202-2211
134. Renga B, Mencarelli A, D'Amore C, Cipriani S, Baldelli F, Zampella A, Distrutti E, Fiorucci S (2012) Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB J 26:3021-3031
135. Seyer P, Vallois D, Poitry-Yamate C, Schütz F, Metref S, Tarussio D, Maechler P, Staels B, Lanz B, Grueter R, Decaris J, Turner S, da Costa A, Preitner F, Minehira K, Foretz M, Thorens B (2013) Hepatic glucose sensing is required to preserve β cell glucose competence. J Clin Invest 123:1662-1676
136. Düfer M, Hörth K, Wagner R, Schittenhelm B, Prowald S, Wagner TFJ, Oberwinkler J, Lukowski R, Gonzalez FJ, Krippeit-Drews P, Drews G (2012) Bile acids acutely stimulate insulin secretion of mouse Β-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes 61:1479-1489
137. Renga B, Mencarelli A, Vavassori P, Brancaleone V, Fiorucci S (2010) The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta 1802:363-372
138. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ (2007) Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28:940-946
139. Li G, Kong B, Zhu Y, Zhan L, Williams JA, Tawfik O, Kassel KM, Luyendyk JP, Wang L, Guo GL (2013) Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice. Toxicol Appl Pharmacol 272:299-305
140. Li G, Zhu Y, Tawfik O, Kong B, Williams JA, Zhan L, Kassel KM, Luyendyk JP, Wang L, Guo GL (2013) Mechanisms of STAT3 activation in the liver of FXR knockout mice. Am J Physiol Gastrointest Liver Physiol 305:G829-G837
141. Xu Z, Huang G, Gong W, Zhou P, Zhao Y, Zhang Y, Zeng Y, Gao M, Pan Z, He F (2012) FXR ligands protect against hepatocellular inflammation via SOCS3 induction. Cell Signal 24:1658-1664
142. Deuschle U, Schüler J, Schulz A, Schlüter T, Kinzel O, Abel U, Kremoser C (2012) FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS ONE 7:e43044
143. Ohno T, Shirakami Y, Shimizu M, Kubota M, Sakai H, Yasuda Y, Kochi T, Tsurumi H, Moriwaki H (2012) Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand. Cancer Lett 323:215-222
144. Su H, Ma C, Liu J, Li N, Gao M, Huang A, Wang X, Huang W, Huang X (2012) Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol 303:G1245-G1253
145. Vaquero J, Briz O, Herraez E, Muntané J, Marin JJG (2013) Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds. Biochim Biophys Acta 1833:2212-2219
146. Herraez E, Gonzalez-Sanchez E, Vaquero J, Romero MR, Serrano MA, Marin JJG, Briz O (2012) Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Mol Pharm 9:2565-2576
147. Degirolamo C, Modica S, Vacca M, Di Tullio G, Morgano A, D'Orazio A, Kannisto K, Parini P,Moschetta A (2014) Prevention of spontaneous hepatocarcinogenesis in FXR null mice by intestinal specific FXR re-activation. Hepatology
148. Zhou M, Wang X, Phung V, Lindhout DA, Mondal K, Hsu J, Yang H, Humphrey M, Ding X, Arora T, Learned RM, DePaoli AM, Tian H, Ling L (2014) Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res 74:3306-3316
149. Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, Phung V, To C, Learned RM, Tian H, DePaoli AM, Ling L (2014) A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med 6:247ra100
150. De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, Ventre G, Bentzen CL, Niesor EJ, Dufour J (2004) The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci 49:982-989
151. Lax S, Schauer G, Prein K, Kapitan M, Silbert D, Berghold A, Berger A, Trauner M (2012) Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. Int J Cancer 130:2232-2239
152. Stojancevic M, Stankov K, Mikov M (2012) The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. Can J Gastroenterol 26:631-637
153. Inagaki T, Moschetta A, Lee Y, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA (2006) Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 103:3920-3925
154. Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A (2008) Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res 68:9589-9594
155. Xu Y, Watanabe T, Tanigawa T, Machida H, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Arakawa T (2010) Bile acids induce Cdx2 expression through the farnesoid X receptor in gastric epithelial cells. J Clin Biochem Nutr 46:81-86
156. Chen W, Wang Y, Zhang L, Shiah S, Wang M, Yang F, Yu D, Forman BM, Huang W (2010) Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating Forkhead box M1b transcription. Hepatology 51:953-962
157. García-Rodríguez JL, Barbier-Torres L, Fernández-Álvarez S, Gutiérrez-de Juan V, Monte MJ, Halilbasic E, Herranz D, Álvarez L, Aspichueta P, Marín JJG, Trauner M, Mato JM, Serrano M, Beraza N, Martínez-Chantar ML (2014) SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. Hepatology 59:1972-1983
158. Zhang L, Wang Y, Chen W, Wang X, Lou G, Liu N, Lin M, Forman BM, Huang W (2012) Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. Hepatology 56:2336-2343
159. Seol W, Choi HS, Moore DD (1995) Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol 9:72-85
160. Chong HK, Infante AM, Seo Y, Jeon T, Zhang Y, Edwards PA, Xie X, Osborne TF (2010) Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1. Nucleic Acids Res 38:6007-6017
161. Thomas AM, Hart SN, Kong B, Fang J, Zhong X, Guo GL (2010) Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 51:1410-1419
162. Berrabah W, Aumercier P, Gheeraert C, Dehondt H, Bouchaert E, Alexandre J, Ploton M, Mazuy C, Caron S, Tailleux A, Eeckhoute J, Lefebvre T, Staels B, Lefebvre P (2014) Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). Hepatology 59:2022-2033
163. Song CS, Echchgadda I, Baek BS, Ahn SC, Oh T, Roy AK, Chatterjee B (2001) Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J Biol Chem 276:42549-42556
164. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908-2915
165. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA (2000) Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 275:10638-10647
166. Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart J, Gonzalez FJ, Staels B (2003) Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125:544-555
167. Mi L, Devarakonda S, Harp JM, Han Q, Pellicciari R, Willson TM, Khorasanizadeh S, Rastinejad F (2003) Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell 11:1093-1100
168. Kullak-Ublick GA, Beuers U, Paumgartner G (1996) Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology 23:1053-1060
169. Porez G, Prawitt J, Gross B, Staels B (2012) Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 53:1723-1737
170. Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer J, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JGA, Noel JP, Nicolaou KC, Evans RM (2003) A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 11:1079-1092
171. Dwivedi SKD, Singh N, Kumari R, Mishra JS, Tripathi S, Banerjee P, Shah P, Kukshal V, Tyagi AM, Gaikwad AN, Chaturvedi RK, Mishra DP, Trivedi AK, Sanyal S, Chattopadhyay N, Ramachandran R, Siddiqi MI, Bandyopadhyay A, Arora A, Lundåsen T, Anakk SP, Moore DD, Sanyal S (2011) Bile acid receptor agonist GW4064 regulates PPARγ coactivator-1α expression through estrogen receptor-related receptor Α. Mol Endocrinol 25:922-932
172. Cui J, Huang L, Zhao A, Lew J, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F, Wright SD (2003) Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 278:10214-10220
173. Modica S, Gadaleta RM, Moschetta A (2010) Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal 8:e005
174. Liu P, Xu X, Chen L, Ma L, Shen X, Hu L (2014) Discovery and SAR study of hydroxyacetophenone derivatives as potent, non-steroidal farnesoid X receptor (FXR) antagonists. Bioorg Med Chem 22:1596-1607
175. Xu X, Lu Y, Chen L, Chen J, Luo X, Shen X (2013) Identification of 15d-PGJ2 as an antagonist of farnesoid X receptor: molecular modeling with biological evaluation. Steroids 78:813-822
176. Yu DD, Lin W, Chen T, Forman BM (2013) Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery. Bioorg Med Chem 21:4266-4278
177. Di Leva FS, Festa C, D'Amore C, De Marino S, Renga B, D'Auria MV, Novellino E, Limongelli V, Zampella A, Fiorucci S (2013) Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. J Med Chem 56:4701-4717
178. Newton R, Holden NS (2007) Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 72:799-809
179. Stoecklin E, Wissler M, Schaetzle D, Pfitzner E, Groner B (1999) Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol 69:195-204
180. De Martino MU, Alesci S, Chrousos GP, Kino T (2004) Interaction of the glucocorticoid receptor and the chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII): implications for the actions of glucocorticoids on glucose, lipoprotein, and xenobiotic metabolism. Ann N Y Acad Sci 1024:72-85
181. Barbier O, Torra IP, Sirvent A, Claudel T, Blanquart C, Duran-Sandoval D, Kuipers F, Kosykh V, Fruchart J, Staels B (2003) FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 124:1926-1940
182. Shen H, Zhang Y, Ding H, Wang X, Chen L, Jiang H, Shen X (2008) Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell Physiol Biochem 22:1-14
183. Chong HK, Biesinger J, Seo Y, Xie X, Osborne TF (2012) Genome-wide analysis of hepatic LRH-1 reveals a promoter binding preference and suggests a role in regulating genes of lipid metabolism in concert with FXR. BMC Genom 13:51
184. Thomas AM, Hart SN, Li G, Lu H, Fang Y, Fang J, Zhong X, Guo GL (2013) Hepatocyte nuclear factor 4 alpha and farnesoid X receptor co-regulates gene transcription in mouse livers on a genome-wide scale. Pharm Res 30:2188-2198
185. Fujino T, Sato Y, Une M, Kanayasu-Toyoda T, Yamaguchi T, Shudo K, Inoue K, Nishimaki-Mogami T (2003) In vitro farnesoid X receptor ligand sensor assay using surface plasmon resonance and based on ligand-induced coactivator association. J Steroid Biochem Mol Biol 87:247-252
186. Kassam A, Miao B, Young PR, Mukherjee R (2003) Retinoid X receptor (RXR) agonist-induced antagonism of farnesoid X receptor (FXR) activity due to absence of coactivator recruitment and decreased DNA binding. J Biol Chem 278:10028-10032
187. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA (2004) Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 18:157-169
188. Unno A, Takada I, Takezawa S, Oishi H, Baba A, Shimizu T, Tokita A, Yanagisawa J, Kato S (2005) TRRAP as a hepatic coactivator of LXR and FXR function. Biochem Biophys Res Commun 327:933-938
189. Balasubramaniyan N, Ananthanarayanan M, Suchy FJ (2012) Direct methylation of FXR by Set7/9, a lysine methyltransferase, regulates the expression of FXR target genes. Am J Physiol Gastrointest Liver Physiol 302:G937-G947
190. Rizzo G, Renga B, Antonelli E, Passeri D, Pellicciari R, Fiorucci S (2005) The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol 68:551-558
191. Ananthanarayanan M, Li S, Balasubramaniyan N, Suchy FJ, Walsh MJ (2004) Ligand-dependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1. J Biol Chem 279:54348-54357
192. Ananthanarayanan M, Li Y, Surapureddi S, Balasubramaniyan N, Ahn J, Goldstein JA, Suchy FJ (2011) Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis. Am J Physiol Gastrointest Liver Physiol 300:G771-G781
193. Kim D, Lee J, Lee B, Lee JW (2009) ASCOM controls farnesoid X receptor transactivation through its associated histone H3 lysine 4 methyltransferase activity. Mol Endocrinol 23:1556-1562
194. Fang S, Tsang S, Jones R, Ponugoti B, Yoon H, Wu S, Chiang C, Willson TM, Kemper JK (2008) The P300 acetylase is critical for ligand-activated farnesoid X receptor (FXR) induction of SHP. J Biol Chem 283:35086-35095
195. Miao J, Fang S, Lee J, Comstock C, Knudsen KE, Kemper JK (2009) Functional specificities of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. Mol Cell Biol 29:6170-6181
196. Kainuma M, Makishima M, Hashimoto Y, Miyachi H (2007) Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist. Bioorg Med Chem 15:2587-2600
197. Ohno M, Kunimoto M, Nishizuka M, Osada S, Imagawa M (2009) Ku proteins function as corepressors to regulate farnesoid X receptor-mediated gene expression. Biochem Biophys Res Commun 390:738-742
198. Li J, Lu Y, Liu R, Xiong X, Zhang Z, Zhang X, Ning G, Li X (2011) DAX1 suppresses FXR transactivity as a novel co-repressor. Biochem Biophys Res Commun 412:660-666
199. Kemper JK, Xiao Z, Ponugoti B, Miao J, Fang S, Kanamaluru D, Tsang S, Wu S, Chiang C, Veenstra TD (2009) FXR acetylation is normally dynamically regulated by P300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 10:392-404
200. Lien F, Berthier A, Bouchaert E, Gheeraert C, Alexandre J, Porez G, Prawitt J, Dehondt H, Ploton M, Colin S, Lucas A, Patrice A, Pattou F, Diemer H, Van Dorsselaer A, Rachez C, Kamilic J, Groen AK, Staels B, Lefebvre P (2014) Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J Clin Invest 124:1037-1051
201. Renga B, D'Amore C, Cipriani S, Mencarelli A, Carino A, Sepe V, Zampella A, Distrutti E, Fiorucci S (2013) FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. Pharmacol Res 77:1-10
202. Li W, Notani D, Ma Q, Tanasa B, Nunez E, Chen AY, Merkurjev D, Zhang J, Ohgi K, Song X, Oh S, Kim H, Glass CK, Rosenfeld MG (2013) Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature 498:516-520
203. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, Fruchart J, Dallongeville J, Hum DW, Kuipers F, Staels B (2002) Bile acid-activated nuclear receptor FXR suppresses apolipoprotein a-i transcription via a negative FXR response element. J Clin Invest 109:961-971
204. Gardès C, Blum D, Bleicher K, Chaput E, Ebeling M, Hartman P, Handschin C, Richter H, Benson GM (2011) Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-i expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor. J Lipid Res 52:1188-1199
205. Chennamsetty I, Claudel T, Kostner KM, Baghdasaryan A, Kratky D, Levak-Frank S, Frank S, Gonzalez FJ, Trauner M, Kostner GM (2011) Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest 121:3724-3734
206. Lu Y, Heydel J, Li X, Bratton S, Lindblom T, Radominska-Pandya A (2005) Lithocholic acid decreases expression of UGT2B7 in Caco-2 Cells: a potential role for a negative farnesoid X receptor response element. Drug Metab Dispos 33:937-946
207. Miyata M, Matsuda Y, Tsuchiya H, Kitada H, Akase T, Shimada M, Nagata K, Gonzalez FJ, Yamazoe Y (2006) Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase. Drug Metab Pharmacokinet 21:315-323
208. Seok S, Fu T, Choi S, Li Y, Zhu R, Kumar S, Sun X, Yoon G, Kang Y, Zhong W, Ma J, Kemper B,Kemper JK (2014) Transcriptional regulation of autophagy by an FXR-CREB axis. Nature
209. Lee JM, Wagner M, Xiao R, Kim KH, Feng D, Lazar MA, Moore DD (2014) Nutrient-sensing nuclear receptors coordinate autophagy. Nature
210. Wang Y, Chen W, Wang M, Yu D, Forman BM, Huang W (2008) Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48:1632-1643
211. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S (2009) The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183:6251-6261
212. Gadaleta RM, Oldenburg B, Willemsen ECL, Spit M, Murzilli S, Salvatore L, Klomp LWJ, Siersema PD, van Erpecum KJ, van Mil SWC (2011) Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κb signaling in the intestine. Biochim Biophys Acta 1812:851-858
213. Pawlak M, Baugé E, Bourguet W, De Bosscher K, Lalloyer F, Tailleux A, Lebherz C, Lefebvre P, Staels B (2014) The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. Hepatology 60:1593-1606
214. Houten SM, Volle DH, Cummins CL, Mangelsdorf DJ, Auwerx J (2007) In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue. Mol Endocrinol 21:1312-1323
215. Hatori M, Vollmers C, Zarrinpar A, DiTacchio L, Bushong EA, Gill S, Leblanc M, Chaix A, Joens M, Fitzpatrick JAJ, Ellisman MH, Panda S (2012) Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab 15:848-860
216. Zhang YJ, Guo GL, Klaassen CD (2011) Diurnal variations of mouse plasma and hepatic bile acid concentrations as well as expression of biosynthetic enzymes and transporters. PLoS ONE 6:e16683
217. Pan X, Zhang Y, Wang L, Hussain MM (2010) Diurnal regulation of MTP and plasma triglyceride by CLOCK is mediated by SHP. Cell Metab 12:174-186
218. Lee J, Seok S, Yu P, Kim K, Smith Z, Rivas-Astroza M, Zhong S, Kemper JK (2012) Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice. Hepatology 56:108-117
219. Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13:251-262
220. Purushotham A, Xu Q, Lu J, Foley JF, Yan X, Kim D, Kemper JK, Li X (2012) Hepatic deletion of SIRT1 decreases hepatocyte nuclear factor 1α/farnesoid X receptor signaling and induces formation of cholesterol gallstones in mice. Mol Cell Biol 32:1226-1236
221. Gineste R, Sirvent A, Paumelle R, Helleboid S, Aquilina A, Darteil R, Hum DW, Fruchart J, Staels B (2008) Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol Endocrinol 22:2433-2447
222. Frankenberg T, Miloh T, Chen FY, Ananthanarayanan M, Sun A, Balasubramaniyan N, Arias I, Setchell KDR, Suchy FJ, Shneider BL (2008) The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology 48:1896-1905
223. Balasubramaniyan N, Luo Y, Sun A, Suchy FJ (2013) SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes. J Biol Chem 288:13850-13862
224. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, Wilson-Pérez HE, Sandoval DA, Kohli R, Bäckhed F, Seeley RJ (2014) FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509:183-188
225. Kuipers F, Groen AK (2014) FXR: the key to benefits in bariatric surgery? Nat Med 20:337-338
226. Adorini L, Pruzanski M, Shapiro D (2012) Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 17:988-997
227. Kemper JK (2011) Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications. Biochim Biophys Acta 1812:842-850
228. Lew J, Zhao A, Yu J, Huang L, De Pedro N, Peláez F, Wright SD, Cui J (2004) The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J Biol Chem 279:8856-8861
229. Bramlett KS, Yao S, Burris TP (2000) Correlation of farnesoid X receptor coactivator recruitment and cholesterol 7alpha-hydroxylase gene repression by bile acids. Mol Genet Metab 71:609-615